Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kodiak SciencesMEX:KOD 27 Return-on-Tangible-Asset is -70.82% as of Mar. 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Kodiak Sciences ranks worse than 73.09% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kodiak Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN-4,194.98 Mil. Kodiak Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was MXN5,923.86 Mil. Therefore, Kodiak Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -70.82%.
The historical rank and industry rank for Kodiak Sciences's Return-on-Tangible-Asset or its related term are showing as below:
MEX:KOD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -363.8 Med: -44.35 Max: -18.66
Current: -80.64
During the past 10 years, Kodiak Sciences's highest Return-on-Tangible-Asset was -18.66%. The lowest was -363.80%. And the median was -44.35%.
MEX:KOD's Return-on-Tangible-Asset is ranked worse than 73.09% of 1416
companies
in the Biotechnology industry
Industry Median: -35.915
vs MEX:KOD: -80.64
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kodiak Sciences Return-on-Tangible-Asset Related Terms
Kodiak Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kodiak Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:KOD vs ABCL, AGIO, IMNM: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Kodiak Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -70.82% mean?
Kodiak Sciences (MEX:KOD) has a Return-on-Tangible-Asset of -70.82% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #1035 out of 1416 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Kodiak Sciences' Return-on-Tangible-Asset too high?
Kodiak Sciences' current Return-on-Tangible-Asset is -70.82%. Based on the distribution chart, Kodiak Sciences ranks #1035 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Return-on-Tangible-Asset compare to ABCL and AGIO?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #1035 out of 1416 companies for Return-on-Tangible-Asset. This places Kodiak Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current Return-on-Tangible-Asset is -70.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current Return-on-Tangible-Asset of -70.82%. The current Return-on-Tangible-Asset is -70.82%. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current Return-on-Tangible-Asset is -70.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score
Get the complete analysis for MEX:KOD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KOD has been successfully added to your 
